SpliceBio
Biotechnology company developing next-generation gene therapies using a proprietary protein splicing platform.
About
SpliceBio is a biotechnology company focused on developing next-generation gene therapies. Their proprietary Protein Splicing platform is designed to overcome the limitations of traditional gene therapy by enabling the delivery of large genes, which are often implicated in genetic diseases. This technology is based on extensive research in protein engineering and intein biology, originating from Princeton University, and aims to provide new therapeutic options for diseases currently lacking effective treatments. Teams look it up for Biotechnology, HealthTech, Gene Therapy.
Frequently asked
What does SpliceBio do?
SpliceBio is a Biotechnology company that offers Services. Teams look it up for HealthTech, Gene Therapy, Biotech. It is based in Cambridge, United States and was founded in 2021. Public records show $100M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has SpliceBio raised?
SpliceBio has raised a total of $100M in funding. The most recent round on record is Series B.
Where is SpliceBio headquartered?
SpliceBio is headquartered in Cambridge, United States.
When was SpliceBio founded?
SpliceBio was founded in 2021.
What industry does SpliceBio operate in?
SpliceBio operates in Biotechnology, HealthTech, Gene Therapy, Biotech, Drug Discovery.
What is SpliceBio's current status?
SpliceBio's current operating status is: Inactive.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.